94 related articles for article (PubMed ID: 23050745)
1. Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.
Kim H; Kim NH; Kang HJ; Lee JW; Kim MS; Park KD; Shin HY; Ahn HS
Pediatr Transplant; 2012 Dec; 16(8):910-2. PubMed ID: 23050745
[No Abstract] [Full Text] [Related]
2. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
Magro L; Catteau B; Coiteux V; Bruno B; Jouet JP; Yakoub-Agha I
Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
[TBL] [Abstract][Full Text] [Related]
3. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
de Masson A; Bouaziz JD; Peffault de Latour R; Wittnebel S; Ribaud P; Rubio MT; Micol JB; Suarez F; Nguyen S; Dalle JH; Yakouben K; Robin M; Xhaard A; Adès L; Bourhis JH; Rybojad M; Bagot M; Socié G
Blood; 2012 Dec; 120(25):5089-90. PubMed ID: 23243159
[No Abstract] [Full Text] [Related]
4. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
Moreno-Romero JA; Fernández-Avilés F; Carreras E; Rovira M; Martínez C; Mascaró JM
Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
[No Abstract] [Full Text] [Related]
5. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
Lazar J; Poonawalla T; Teng JM
Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].
Martínez C
Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():69-71. PubMed ID: 21381292
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
[TBL] [Abstract][Full Text] [Related]
8. Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?
Papadakis V; Karakasis D; Sfikakis PP; Baltadakis I; Apostolidis J; Evangelou K; Gorgoulis VG; Harhalakis N
Leuk Lymphoma; 2009 Mar; 50(3):471-4. PubMed ID: 19253137
[No Abstract] [Full Text] [Related]
9. Is imatinib mesylate a promising drug in systemic sclerosis?
van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
[TBL] [Abstract][Full Text] [Related]
10. Long-term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft-versus-host disease.
Bisaccia E; Palangio M; Gonzalez J
Transfus Apher Sci; 2011 Oct; 45(2):187-90. PubMed ID: 21890415
[TBL] [Abstract][Full Text] [Related]
11. Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?
Chunduri S; Dobogai LC; Bruno A; Kadkol S; Rondelli D
Leukemia; 2005 Mar; 19(3):456-7; author reply 457. PubMed ID: 15674413
[No Abstract] [Full Text] [Related]
12. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
Kay J; High WA
Arthritis Rheum; 2008 Aug; 58(8):2543-8. PubMed ID: 18668587
[TBL] [Abstract][Full Text] [Related]
13. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
Taïeb A; Constans J; Mahon FX
Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
[No Abstract] [Full Text] [Related]
14. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.
Okamoto M; Okano A; Akamatsu S; Ashihara E; Inaba T; Takenaka H; Katoh N; Kishimoto S; Shimazaki C
Leukemia; 2006 Jan; 20(1):172-3. PubMed ID: 16239908
[No Abstract] [Full Text] [Related]
15. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
Tolland JP; Devereux C; Jones FC; Bingham EA
Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis.
Owsianowski M; Gollnick H; Siegert W; Schwerdtfeger R; Orfanos CE
Bone Marrow Transplant; 1994 Nov; 14(5):845-8. PubMed ID: 7889018
[TBL] [Abstract][Full Text] [Related]
17. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
[TBL] [Abstract][Full Text] [Related]
18. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.
Millot F; Guilhot J; Nelken B; Leblanc T; De Bont ES; Békassy AN; Gadner H; Sufliarska S; Stary J; Gschaidmeier H; Guilhot F; Suttorp M
Leukemia; 2006 Feb; 20(2):187-92. PubMed ID: 16341042
[TBL] [Abstract][Full Text] [Related]
20. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
Perz JB; Khorashad JS; Marin D; Apperley JF; Olavarria E
Haematologica; 2006 Aug; 91(8):1145-6. PubMed ID: 16870551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
